IM8 Secures US$1 Billion Growth Funding, Signalling Confidence in Premium Supplement Sector

Prenetics Global’s IM8 brand, co-founded by David Beckham, has received a US$1 billion growth funding commitment from General Catalyst’s Customer Value Fund (CVF). This capital injection suggests growing investor interest in premium, celebrity-backed brands within the global supplement industry, particularly those targeting the longevity sector. IM8 markets a powder product, which it states is 'NASA research-backed' and focused on longevity. The brand reports commercial activity including over 50 million servings delivered and approximately 200,000 monthly subscribers. Monthly revenue for IM8 is reported at US$17 million. ### Revenue Projections Following the funding announcement, Prenetics has revised its 2026 revenue guidance for IM8. The updated projection is US$210-220 million, an increase from the previously anticipated US$190-210 million. IM8 has also stated it is the 'fastest-growing premium supplement brand ever recorded', though specific industry benchmarks for this claim were not detailed. ### Investment Structure and Market Context General Catalyst’s Customer Value Fund provides growth funding, which differs from traditional equity investments. The specific terms and conditions of this non-equity stake funding have not been fully disclosed. This investment occurs within a global supplement market that continues to expand, with growth observed in premium, personalised, and longevity-focused products. Celebrity endorsements have historically been a driver of consumer interest and sales within this sector. The scale of this financial commitment to IM8 suggests a belief in the brand's business model and its potential to capitalise on these market trends, which may influence broader investment strategies and product development across the industry. ### Industry Implications While the specifics of the 'NASA research' supporting IM8's product claims remain to be detailed, and the verifiable context for its 'fastest-growing premium brand' assertion is yet to be fully established, the US$1 billion funding indicates a significant financial endorsement. This development could signal to other industry players the potential for returns in the premium and celebrity-endorsed supplement categories, potentially stimulating further investment and innovation in these areas.